Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials

Dermaliq Therapeutics, Inc. is an independent private pharmaceutical company emerged from Novaliq Spin-off to unlock value in the space of medical dermatology by using Novaliq's transformative technology outside eye care 3E Bioventures Capital and Be... Biopharmaceuticals, Dermatology, Venture Capital Dermaliq Therapeutics, alopecia, psoriasis, soft tissue infection
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news